Philip Morris, British American Tobacco & the Global Nicotine Market: Reduced-Risk Products' Hurdles to Growth
Former Regional Head, Product Compliance and RRP QA at Philip Morris International
inpractise.com/articles/philip-morris-british-american-tobaccoand-thee-global-nicotine-market-reduced-risk-products-hurdles-to-growth
Philip Morris, British American Tobacco & the Global Nicotine Market: Reduced-Risk Products' Hurdles to Growth(July 30, 2024)
Former Regional Head, Product Compliance and RRP QA at Philip Morris International
Interview Transcript
This is a snippet of the transcript, sign up to read more.
So initially, you were working with regulators to help them understand heated tobacco products, and then at Imperial, you focused on launching these products. Is that correct? Great. I have many questions. One thing that strikes me is the varying importance of vaping products, heated tobacco products, and modern oral products in different markets. Could you help me understand why there are such differences in adoption across various markets?
In terms of why smokers might be attracted to heated tobacco products, it's mainly because it's the most familiar product in the new category to their smoking experience, if you want to put it that way. Plus, it comes with some benefits. It's proven to be less harmful, which is a key driver. Additionally, there's no ash, less odor, and it doesn't leave your clothes, hair, or fingers smelling, making it a nice evolution from smoking to using a product like this.
This is a snippet of the transcript, sign up to read more.
Related Content
Swedish Match, Snus, & Smokefree Tobacco Products
Former Managing Director at Swedish Match
Philip Morris: Reduced Risk Products & Consumer Behavior
Former VP of Marketing at Japan Tobacco
Perimeter Solutions, ZYN, Computer Modelling Group, MTU Aero, FTAI, RTX, Loar, PM, LX, Becle, Macfarlane, Auto Partner
Lifco vs Halma, Danaher, Eurofins, Waters Corp, PM & BAT, Wayfair vs AMZN, Ocado, MongoDB
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.